SCHEMBL8205948

SCHEMBL8205948

CCCCOC(=O)c1ccc(N2CCN(CCC)CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.56
TSHR P16473 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
LMNA P02545 2/20 0.55
CYP1A2 P05177 2/20 0.55
CYP2C19 P33261 2/20 0.55
CYP2D6 P10635 2/20 0.55
ESR1 P03372 1/20 0.55
MAPK1 P28482 1/20 0.55
NR1H2 P55055 1/20 0.55
RNASEL Q05823 1/20 0.55
CYP3A4 P08684 1/20 0.54
CYP2C9 P11712 1/20 0.54
PDE4D Q08499 1/20 0.54
THRA P10827 1/20 0.53
THRB P10828 1/20 0.53
MAPT P10636 3/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
KMT2A Q03164 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10900983 0.88 STS (0.48) TSHRSMN1; SMN2LMNACYP1A2CYP2C19
SCHEMBL8205972 0.88 ALDH1A1 (0.58) DRD2TSHRLMNAMAPTKMT2A
SCHEMBL10900785 0.87 MAPT (0.55) DRD2TSHRTHRATHRBMAPT
SCHEMBL8523468 0.85 SMN1; SMN2 (0.66) TSHRSMN1; SMN2LMNACYP1A2CYP2C19
SCHEMBL6678636 0.84 SMN1; SMN2 (0.67) TSHRSMN1; SMN2LMNACYP1A2CYP2C19
SCHEMBL4652187 0.83 DRD2 (0.61) DRD2TSHRSMN1; SMN2LMNAMAPT
SCHEMBL10901028 0.83 KDM4E (0.59) TSHRTHRATHRBHRH2HRH1
SCHEMBL3918577 0.83 TSHR (0.56) TSHRSMN1; SMN2LMNACYP1A2CYP2C19
SCHEMBL10901318 0.82 KMT2A (0.57) DRD2TSHRSMN1; SMN2MAPTKMT2A
Hydrochloric Acid SCHEMBL10897562 0.82 KDM4E (0.58) TSHRTHRATHRBHRH2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009956-A1 NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS Glaxo Group Limited , a corporation 2010-01-14 US disclosed
US-20100009956-A1 NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS Glaxo Group Limited , a corporation 2010-01-14 US disclosed
EP-2030621-A1 Novel substituted pyrimidines as cysteine protease inhibitors GLAXO GROUP LIMITED (GB) 2009-03-04 EP disclosed
WO-2008052934-A1 NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS GLAXO GROUP LIMITED (GB) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009956-A1 NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS SERPINB1, CTRL, PRSS1 DRD2 4554/4885TSHR 4736/4885SMN1; SMN2 2778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.